-
Signature
-
/s/ Stacie Aarestad, Attorney-in-fact
-
Issuer symbol
-
N/A
-
Transactions as of
-
18 Feb 2022
-
Net transactions value
-
+$20,549
-
Form type
-
4
-
Filing time
-
22 Feb 2022, 20:34:29 UTC
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
AGTC |
Common Stock |
Options Exercise |
$42,240 |
+120,686 |
+374% |
$0.3500 |
152,971 |
18 Feb 2022 |
Direct |
|
| transaction |
AGTC |
Common Stock |
Sale |
$21,691 |
-9,950 |
-6.5% |
$2.18 |
143,021 |
18 Feb 2022 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
AGTC |
Stock Option (right to buy) |
Options Exercise |
$0 |
-120,686 |
-100% |
$0.000000* |
0 |
18 Feb 2022 |
Common Stock |
120,686 |
$0.3500 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
The reporting person undertakes to provide to Applied Genetic Technologies Corporation, any security holder of Applied Genetic Technologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above.